Chugai Pharmaceutical Announcement Anti-Cancer Agent Tarceva Tablet Approved in Japan (Japan)
This article was originally published in PharmAsia News
Chugai Pharmaceutical Co. announced Oct. 22 that the Japanese Ministry of Health Labour and Welfare has granted approval to Tarceva. The drug has been approved for use in patients with certain types of lung-cancer that can be aggravated by chemotherapy. The Ministry of Health's decision comes on the heels of several successful clinical trials which revealed Tarceva was safe and effective and had a low incidence of side effects. The drug has been approved for marketing in doses of 25 mg, 100 mg, and 150 mg. (Click here for more
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.